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Lactococcus lactis is being developed as a vaccine delivery system as it bears no 
threat to animal and human health. It has been used for centuries in the fermentation 
of foods and is generally recognised as safe. However, a safety factor pertaining to 
the type of selectable marker present on the vector system poses to be of concern. 
Chances of the transfer of antibiotic resistance genes, usually employed by vectors as 
selectable markers, into the natural environment become a possible risk. Therefore, 
there is a need for the development of ideal vectors without such selectable markers 
(Dertzbaugh, 1998). 
The activity of the xylanase gene of Bacillus coagulans ST -6 can be detected on 
Remazol Brilliant Blue-Xylan (RBB-Xylan) as a clear halo zone against a dark blue 
background. This characteristic allows xylanase to be used as a selectable 
chromogenic marker on any vector system. On the other hand, the matrix or 
membrane (M) protein of Newcastle disease virus (NDV) strain AF 2240 can be 
useful as an antigen to generate antibody response towards NDV infection in 
chickens. 
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Both, the xylanase gene (0.8 kb) of B. coagulans ST-6 and the M gene (1.1 kb) of 
NDV strain AF 2240 were cloned in lactococcal expression vector pMG36e and 
transformed into Escherichia coli XLI-blue MRF'. The recombinant plasmids, 
pMG36e-X and pMG36e-X-M were sub-cloned into L. lactis MG 1363 via 
electroporation. The insertion and orientation of the xylanase gene was confmned 
using restriction enzyme analysis and PCR amplification. Xylanase activity and 
expression on RBB-Xylan agar plates further confmned its presence in the 
recombinant plasmid pMG36e-X. In addition, the enzyme activity was also 
quantitatively showed using the Somogyi-Nelson assay. The sequence of the M gene 
obtained in clone pMG36e-X-M from L. lactis MG 1363 was found to be 99% 
homologous to the established sequence (Jemain, 1999). Expression of the fusion M 
protein was studied at the transcriptional leve1. RT -PCR was used to detect the 
transcription of the gene using RNA of L. lactis MG1363 containing the recombinant 
plasmid pMG36e-X-M as template. The size of the RT-PCR product correlated with 
the size of the cloned M gene (1.1 kb). In addition, the RT-PCR product was 
sequenced to confirm the presence of the M gene. 
Based on the results obtained, recombinant plasmids pMG36e-X and pMG36e-X-M 
were successfully constructed and introduced into E. coli XLI-blue-MRF' and L. 
lactis MG1363. The recombinant DNA pMG36e-X is capable of expressing the 
xylanase gene and can be further developed as a chromogenic selection marker for a 
new and improved food-grade shuttle vector for E. coli and L. lactis. On the other 
hand, expression of the fusion M gene was detected at transcriptional level in 
recombinant clone pMG36e-X-M. 
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Lactococcus lactis dikaji sebagai agen pengangkutan vaksin kerana ia tidak 
membahayakan kesihatan haiwan dan manusia. la digunakan dalam proses 
fermentasi makanan sejak beratusan tahun dahulu dan sehingga kini dianggap 
selamat. Isu tentang faktor keselamatan berkenaan jenis penanda pilihan dalam 
sistem vektor diberikan perhatian. Gen penahanan antibiotik selalu digunakan dalam 
vektor sebagai penanda pilihan dan pemindahannya ke dalam keadaan semulajadi 
mungkin mendatangkan risiko. Dengan itu, pembinaan vektor yang tidak 
menggunakan penanda pilihan sebegini adalah memanfaatkan (Dertzbaugh, 1998). 
Enzim xilanase daripada Bacillus coagulans ST -6 boleh dikesan sebagai zon cerah 
terhadap latar belakang yang biro menggunakan Remazol Brilliant Blue-Xylan 
(RBB-Xylan). Sifat ini menjadikan gen xilanase berpotensi sebagai penanda pilihan 
jenis kromogenik dalam sebarang sistem vektor. Sebaliknya, matrix atau membran 
(M) protein yang immunogenik daripada virus penyakit Newcastle (NDV) strain 
AF2240 boleh digunakan sebagai antigen untuk menghasilkan tindakbalas antibodi 
terhadap jangkitan NDV di dalam ayam. 
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Gen xilanase (0.8 kb) daripada B. coagulans ST -6 dan gen M (1.1 kb) danpada NDV 
strain AF 2240 telah diklonkan ke dalarn vektor pengekspres pMG36e dan 
dipindahkan ke dalam Escherichia coli XLI-blue MRF'. Kedua-dua plasmid 
rekombinan pMG36e-X dan pMG36e-X-M ini dipindahkan ke dalam L. lactts 
MGI363 secara "electroporation". Pengesahan dan penentuan orientasi gen xilanase 
dibuat dengan penganalisasi enzim pembatas dan amplifikasi DNA secara PCR. 
Aktiviti dan ekspresi xilanase di atas RBB-X ylan mengesahkan kehadirannya dalarn 
plasmid rekombinan pMG36e-X serta penentuan activiti enzim xilanase secara 
kuantitatif dilaksanakan dengan cara Somogyi-Nelson. Jujukan DNA gen M dalam 
klon pMG36e-X-M daripada L. [actls MG 1363 menunjukkan bahawa ia mempunyai 
homologi sebanyak 99% berbanding dengan jujukan DNA yang telah ditentukan 
(Jemain, 1999). Pengekspresan gen M pada tahap transkripsi ditentukan. Cara yang 
digunakan untuk mengkajinya ialah secara RT -PCR menggunakan RNA daripada L. 
lactls MG1363 yang mempunyai plasmid rekombinan pMG36e-X-M. Produk yang 
diperolehi daripada RT-PCR adalah bersaiz 1.1 kb iaitu sarna saiz dengan gen M 
yang diklonkan. Penentuan jujukan DNA daripada produk RT-PCR juga 
dilaksanakan untuk memastikan kehadiran gen M. 
Berdasarkan kepada keputusan yang diperolehi, plasmid rekombinan pMG36e-X dan 
pMG36e-X-M telah berjaya direkabentuk dan dimaukkan ke dalarn E. coli XLI-blue-
MRF' dan L. lactls MG1363. Plasmid rekombinan pMG36e-X marnpu 
megekspreskan enzim xilanase dan boleh digunakan sebagai penanda pilihan jenis 
kromogenik untuk menghasilkan vektor "food-grade" yang mempunyai ciri-ciri yang 
lebih baik untuk E. coli and L. lactis. Sebaliknya, pengekspresan gen M telah 
dipastikan pada tahap transkripsi mRNA. 
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CHAPTER I 
INTRODUCTION 
The ability of the host immune system to recognise and neutralise invading foreign 
organisms is the basis of defense mechanism against infectious agents (Y ong Kang, 
1989). Vaccination has been practiced for over 2 centuries since Edward Jenner, 
who, in 1796 attributed the first scientific attempts to control an infectious disease 
(small pox) (Brown et al. , 1993). In addition, vaccination is the most cost effective 
means to control viral diseases in poultry and pigs industries. Outbreak of viral 
diseases may cause substantial economic losses. In general, conventional viral 
vaccines used for disease control have potential risks. Live attenuated viruses used 
as vaccine carries the risk that they might revert to a virulent state and establish 
persistent or latent infection. On the other hand, killed or inactivated virus vaccine 
may lead to disease outbreaks if inadequately inactivated or mutation of the wild­
type virus will result in the existence of a highly resistance virus. Recent advances in 
biotechnology especially molecular biology and protein chemistry have offered 
prospects for the development of a new generation of vaccines that are safer, cheaper 
and more effective which are mainly genetically engineered vaccines. 
Bacterial-based systems as live vectors for the delivery of heterologous antigens 
offer a number of advantages as a vaccination strategy. Both Gram-negative and 
Gram-positive bacteria have been investigated for the delivery of foreign antigens. 
The current knowledge of molecular biology and genetics as well as recombinant 
DNA techniques has allowed the insertion of genes encoding the antigens to be 
delivered, into non-pathogenic carrier for expression (Liljeqvist and Stahl, 1999). 
Among the Gram-positive bacteria, Lactococcus are designated GRAS or 'generally 
recognised as safe' organisms, which are traditionally used in the preservation of 
foods and the development of flavour and texture in the final product. Furthermore, 
they are non-pathogenic, non-invasive, non-colonising and they bare no threat to 
human and animal health. They also have the capacity to secrete proteins allowing 
surface expression or extracellular production of heterologous enzymes or proteins. 
These features render them to be the ideal choice for the safe production of 
commercially significant foreign proteins and medical applications (van de Guchte et 
al. , 1992; Leenhouts and Venema, 1992; 1993). Developments in genetic 
manipulation have given these Gram-positive lactic acid bacteria (LAB) the 
advantage to be used as a host expression system for antigen delivery to induce 
immune response (Wells et al. , 1993b; Robinson et al. , 1997). 
The type of selectable marker present on vaccine delivery vector system is a matter 
of great concern. Vectors require a selective property usually antibiotic resistance 
gene such as ampicillin, streptomycin and erythromycin resistance gene. This type 
of vector system may carry the risk of anaphylactic reaction in the recipient and the 
possible transfer of the resistance gene into the natural environment often resulting in 
the emergence of new drug resistant pathogens (Dertzbaugh, 1998). Therefore, 
development of the LAB for use as a vaccine delivery vehicle to be devoid of 
antibiotic resistance genes can be seen as the safer alternative. Suitable chromogenic 
genes may replace antibiotic resistance genes as the selectable marker in vector 
systems. An example of a suitable chromogenic marker is the xylanase gene of 
Bacillus coagulans ST -6, which has the ability to hydrolyse glycosidic linkages of 
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the xylan polysaccharide. The activity of this enzyme can be detected on a suitable 
substrate such as Remazol Brilliant Blue-Xylan (RBB-Xylan) as a clear halo zone 
against a dark blue background (Biely et al. , 1985). Hence, this characteristic gives 
xylanase the potential to be used as a selectable marker on any vector system. 
On the other hand, the matrix or membrane (M) protein of Newcastle disease virus 
(NDV), a negative-strand RNA virus belonging to the Paramyxoviridae family 
(Faa berg and Peebles, 1988) can be useful as an antigen to generate antibody 
response towards NDV infection in chickens. NDV causes severe respiratory 
infection in poultry requiring control by vaccination or quarantine with slaughter of 
all birds in confirmed outbreaks. Successful cloning of the immunogenic M gene in 
a food-grade vector system without antibiotic resistance selectable marker and 
followed by the expression of the fusion protein in a Lactococcus may be an 
interesting approach in the development of vaccine delivery systems. 
Objectives 
The objectives of this study are: 
1 .  to clone the xylanase gene from B. coagulans ST -6 in the lactococcal 
expression vector pMG36e and to express it in L. lactis MG 1363, 
2. to clone the M gene from NDV strain AF 2240 in the newly constructed 
plasmid, pMG36e-X, and 
3. to analyse the expression of the fused M gene in L. lactis MG1363 at the 
transcriptional level. 
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CHAPTERll 
LITERATURE REVIEW 
Viral Vaccine 
Introduction 
Defense against infectious agents relies on the ability of the host immune system to 
recognise and neutralise the invading organism. To prevent virus infection, 
vaccination has been practiced for over two centuries since the time of Edward 
Jenner, as it is the most important and cost-effective means to control and prevent 
infectious diseases such as viral diseases in poultry and pigs industries apart from 
quarantine and other strategies to eradicate diseases. Outbreak of viral diseases can 
cause substantial barriers to international trade in animal and animal products. The 
successful development of vaccines has kept many major diseases under control. 
Yet, there is a growing need for improvements of existing vaccines in terms of 
increased efficacy and improved safety (Yong Kang, 1989; Liljeqvist and Stahl, 
1999). Better technological possibilities, combined with increased knowledge in 
related fields, such as immunology and molecular biology, allow new vaccination 
strategies. However, relatively little changes have been made and the immunogens 
widely used today are killed or live attenuated viruses, for example measles, rubella 
and polio vaccine (plotkin, 1993). Live virus vaccines carry the risk that they may 
revert to a virulent state, which may then lead to disease when using virus especially 
in immunocompromised hosts. Likewise, killed or inactivated virus vaccines also 
have potential risks; such as inadequate inactivation could lead to disease outbreaks 
caused by residual active wild-type virus in the vaccine. Moreover, mutation of the 
wild-type virus could result in the existence of a highly resistance virus (Y ong Kang, 
1989). 
Recent attention has focused upon the design and production of 'subunit vaccines' 
consisting of non-viable or non-replicating and non-infectious portions of the 
pathogenic agent that are still capable of eliciting a protective immune response. 
This type of vaccine is attractive because it circumvents some of the concerns 
associated with intact viral immunogens, such as incomplete inactivation or 
unsatisfactory attenuation of the virus stock and possible biological contamination of 
the vaccine (Yong Kang, 1989). 
Advances in biotechnology especially molecular biology and protein chemistry 
technologies, offer prospects in the development of safer, cheaper and more effective 
vaccines and the possibility of the production of highly purified biologically active 
protein subunits directed towards the preparation of protein subunit vaccines. In 
addition, recombinant DNA technology are now dominating in the strive for ideal 
vaccines against infectious agents which cannot be cultivated (Yong Kang, 1989). 
Conventional Viral Vaccines 
Conventional viral vaccmes for disease control in animals relied upon two 
approaches; inactivated vaccines and live attenuated vaccines. The former requires 
large-scale cultivation of the virus followed by specific inactivation and delivery 
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with an appropriate adjuvant to boost the animal's immune response. Immunity 
generated by this inactivated vaccines tends to be short lived� consequently frequent 
revaccination is required to maintain individual and herd immunity (Dertzbaugh, 
1998). 
As for the live attenuated vaccines, attenuation is achieved by multiple passages of 
the virus in a suitable laboratory host sometimes under aberrant culture conditions 
(e.g. cold temperature) or by the use of a naturally attenuated virus strain or a related 
virus from a similar host species (Dertzbaugh, 1998). 
New Generation Viral Vaccines 
Molecular biology has opened up entirely new approaches to the development of 
vaCCInes. Advanced strategies are employed for the production of genetically 
engineered subunit viral vaccines. 
Ribosomal DNA and expression systems allow the large-scale production of viral 
antigens from suitable procaryotes and eukaryotes to be used as effective and 
protective vaccines. The power of recombinant DNA techniques allows portions of 
viral antigens to be expressed alone or as fusions (Yong Kang, 1989). Effective 
vaccine antigens have been produced with the expressed viral antigen, such as the 
hepatitis B surface antigen expressed in yeast (McAleer et at., 1984). 
In general, determinants of surface antigens (mainly proteins) are responsible for the 
induction of neutralising antibodies and hence induce immunity. Virus neutralisation 
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is mediated mainly by the binding of antibody to one or more portions of a viral 
surface protein required for some initial steps in virus infection. Thus, the primary 
target for antiviral vaccine development is an antigenic surface protein(s) of a virus 
(Yong Kang, 1989). However, it has been reported that neutralising antibodies alone 
is not sufficient for protection (Boere et ai. , 1983; Me10en et ai. , 1983). Internal 
antigens may act as a secondary target and it is also possible that an antigen that fails 
to induce neutralising antibodies can still induce an antibody that provides protection 
against disease. Despite the fact that the mechanism of such protection is not well 
documented but it may well be advantageous to use an internal core antigen or other 
antigens that do not elicit a neutralising antibody response when preparing subunit 
vaccine using recombinant DNA techniques. These antigens which induce non­
neutralising antibodies should be considered as useful targets for vaccine 
development. 
LAB as an Antigen and Enzyme Delivery System 
Bacterial-based expression systems are the most convenient to use and they can 
express antigen( s) at very high levels. Although various studies on the development 
of recombinant bacteria for antigen delivery have been reported, they are often 
focused on the use of pathogenic bacteria (Aldovini and Young, 199 1; Chatfield et 
al. , 1992; Stover et al. , 1993). On the contrary, the LAB offer a useful expression 
system for the production of large quantities of desired gene products for the 
induction of immune response, as they bear no threat to animal and human health. 
Moreover, the LAB is non-pathogenic, non-invasive and non-colonising and they 
have been used for centuries in the fermentation of foods and are generally 
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